Interferon (IFN)-β treatment enhances CD95 and interleukin 10 expression but reduces interferon-γ producing T cells in MS patients

Journal of Neuroimmunology

Volumn 96, Issue 1, 1999, Pages 92-100

  Rep, Martin H G ^a   Schrijver, Hans M ^b   Van Lopik, Thea ^a   Hintzen, Rogier Q ^c   Roos, Marijke T L ^a   Adèr, Herman J ^d   Polman, Chris H ^b   Van Lier, René A W ^a  

^a CENTRAL LABORATORY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

CD95; Interleukin 10; Monocytes; Multiple sclerosis; Recombinant interferon (rIFN ); T lymphocyte subsets

Indexed keywords

CD69 ANTIGEN; CD8 ANTIGEN; CYTOKINE; FAS ANTIGEN; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4;

ADULT; ARTICLE; CLINICAL ARTICLE; DEMYELINATING DISEASE; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE DIFFERENTIATION; MALE; MONOCYTE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE SUBPOPULATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD95; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON TYPE II; INTERFERON-BETA; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-2; INTERLEUKIN-4; MALE; MONOCYTES; MULTIPLE SCLEROSIS; RECOMBINANT PROTEINS; SOLUBILITY; T-LYMPHOCYTE SUBSETS;

EID: 0033118470     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(98)00271-9     Document Type: Article

References (35)

1. The IFNB Multiple Sclerosis Study Group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 43:1993;655-661.
2. Arnason B.G.W., Dayal A., Qu Z.X., Jensen M.A., Genc K., Reder A.T. Mechanisms of action of interferon-Beta in multiple sclerosis. Springer. Semin. Immunopathol. 18:1996;125-148.
3. Balkwill F.R. Interferons. Lancet. 1:1989;1060-1063.
4. Brod S.A., Marshall G.D. Jr., Henninger E.M., Sriram S., Khan M., Wolinsky J.S. Interferon-Beta1b treatment decreases tumor necrosis factor-Alpha and increases interleukin-6 production in multiple sclerosis. Neurology. 46:1996;1633-1638.
5. Charlton B., Lafferty K.J. The Th1/Th2 balance in autoimmunity. Curr. Opin. Immunol. 7:1995;793-798.
6. Druet P., Sheela R., Pelletier L. Th1 and Th2 cells in autoimmunity. Clin. Exp. Immunol. 1:1995;9-12. (Suppl. 101).
7. Hamann D., Baars P.A., Hooibrink B., Van Lier R.A.W. Heterogeneity of the human CD4+ T-cell population: two distinct CD4+ T-cell subsets characterized by coexpression of CD45RA and CD45R0 isoforms. Blood. 88:1996;3513-3521.
8. Hintzen R.Q., De Jong R., Lens S.M.A., Brouwer M., Baars P., Van Lier R.A.W. Regulation of CD27 expression on subsets of mature T-lymphocytes. J. Immunol. 151:1993;2426-2435.
9. Hintzen R.Q., Polman C.H. Th-cell modulation in multiple sclerosis. Immunol. Today. 18:1997;507-508.
10. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis - Principles, problems and perspectives. Brain. 120:1997;865-916.
11. Howard M., O'Garra A. Biological properties of interleukin 10. Immunol. Today. 13:1992;198-200.
12. Hughes R.A. Immunotherapy for multiple sclerosis. J. Neurol. Neurosurg. Psychiatr. 57:1994;3-6. Editorial.
13. IFNB Multiple Sclerosis Study Group and Univ. Brit. Columbia, M.S.M.R.I.A.G. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 45:1995;1277-1285.
14. The Multiple Sclerosis Collaborative Research Group (MSCRG), Jacobs L.D., Cookfair D.L., Rudick R.A.et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39:1996;285-294.
15. Jansen P.M., van der Pouw Kraan T.C., de Jong I.W.et al. Release of interleukin-12 in experimental Escherichia coli septic shock in baboons: relation to plasma levels of interleukin-10 and interferon-gamma. Blood. 87:1996;5144-5151.
16. Jung T., Schauer U., Heusser C., Neuman C., Rieger C. Detection of intracellular cytokines by flow cytometry. J. Immunol. Meth. 159:1993;197-207.
17. Khan O.A., Xia Q., Bever C.T. Jr., Johnson K.P., Panitch H.S., Dhib-Jalbut S.S. Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration. Neurology. 46:1996;1639-1643.
18. H2 responses. Immunol. Today. 12:1991;A49-A53.
19. Pachner A.R. Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist. Neurology. 49:1997;647-650.
20. Panitch H.S. Influence of infection on exacerbations of multiple sclerosis. Ann. Neurol. 36:1994;S25-S28. (Suppl.).
21. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group, Paty D.W., Li D.K. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 43:1993;662-667.
22. Pender M.P. Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis. Lancet. 351:1998;978-981.
23. Porrini A.M., Gambi D., Reder A.T. Interferon effects on interleukin-10 secretion - Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients. J. Neuroimmunol. 61:1995;27-34.
24. Porrini A.M., De Luca G., Gambi D., Reder A.T. Effects of an anti-IL-10 monoclonal antibody on rIFNBeta-1b-mediated immune modulation. Relevance to multiple sclerosis. J. Neuroimmunol. 81:1998;109-115.
25. Rep M.H.G., Hintzen R.Q., Polman C.H., Van Lier R.A.W. Recombinant interferon-Beta blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J. Neuroimmunol. 67:1996;111-118.
26. Rudick R.A., Carpenter C.S., Cookfair D.L., Tuohy V.K., Ransohoff R.M. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta. Neurology. 43:1993;2080-2087.
27. Rudick R.A., Ransohoff R.M., Peppler R., Medendorp S.V., Lehmann P., Alam J. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann. Neurol. 40:1996;618-627.
28. Rudick R.A., Ransohoff R.M., Lee J.C.et al. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology. 50:1998;1294-1300.
29. Sibley W.A., Bamford C.R., Clark K. Clinical viral infections and multiple sclerosis. Lancet. 1:1985;1313-1315.
30. Stone L.A., Frank J.A., Albert P.S.et al. The effect of interferon-Beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann. Neurol. 37:1995;611-619.
31. Takizawa T., Fukuda R., Miyawaki T., Ohashi K., Nakanishi Y. Activation of the apoptotic Fas antigen-encoding gene upon influenza virus infection involving spontaneously produced beta-interferon. Virology. 209:1995;288-296.
32. van der Pouw Kraan T.C., Boeije L.C., Smeenk R.J.T., Wijdenes J., Aarden L.A. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J. Exp. Med. 181:1995;775-779.
33. Van Kemenade F.J., Tellegen E., Maurice M.M.et al. Simultaneous regulation of CD2 adhesion and signaling functions by a novel CD2 monoclonal antibody. J. Immunol. 152:1994;4425-4432.
34. Van Lopik, T., Bijl, M., Hart, M., et al., 1998. SLE patients with high levels of sFas are at high risk for developing a relapse (in press).
35. Zipp F., Martin R., Lichtenfels R.et al. Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by soluble recombinant CD95 ligand. J. Immunol. 159(5):1997;2108-2115.